Feasibility and advantage of adding 131I-MIBG to 90Y-DOTATOC for treatment of patients with advanced stage neuroendocrine tumors

EJNMMI Research

Table 4 Results using different normal organ dose limits for subject #8

	Organ dose limits	Maximum activity (GBq)⁹⁰Y-DOTA alone (given over multiple cycles)	Optimum percentage of maximum⁹⁰Y activity to be given when adding MIBG	Acivity (GBq) of¹³¹I-MIBG that can be added without exceeding limits	Tumor dose (cGy):⁹⁰Y-DOTA given alone	Tumor dose (cGy):⁹⁰Y + ¹³¹I
Kidney	2,300	4.9	75	33.3	1,006	2,499
Marrow	300	4.9	75	33.3	1,006	2,499
Kidney	2,300	4.9	87	17.6	1,006	1,794
Marrow	200	4.9	87	17.6	1,006	1,794
Kidney	2,700	5.8	80	30.8	1,180	2,565
Marrow	300	5.8	80	30.8	1,180	2,565